Nuformix (LON:NFX) Reaches New 1-Year Low – Here’s Why
by Renee Jackson · The Cerbat GemNuformix plc (LON:NFX – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday. The stock traded as low as GBX 0.12 and last traded at GBX 0.12, with a volume of 52,582,754 shares trading hands. The stock had previously closed at GBX 0.14.
Nuformix Stock Performance
The stock has a market cap of £3.26 million, a P/E ratio of -4.27 and a beta of 1.53. The firm’s 50-day simple moving average is GBX 0.15 and its 200 day simple moving average is GBX 0.17.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.